Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial

Fig. 2

Linear mixed models were used to compare baseline corrected treatment effects with placebo. Changes in A autonomic balance, B indirect measurements of plasma volume after dapagliflozin (blue circle), exenatide (red square), dapagliflozin plus exenatide (purple upward triangle after 10 days, and 16 weeks of treatment. Data points represent mean with SEM. Statistically significant mean differences of treatments compared with placebo corrected for baseline values are indicated as *(P < 0.05), **(P < 0.01), ***(P < 0.001)

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840